| Literature DB >> 21057507 |
Songlin Li1, Justine J Overman, Diana Katsman, Serguei V Kozlov, Christopher J Donnelly, Jeffery L Twiss, Roman J Giger, Giovanni Coppola, Daniel H Geschwind, S Thomas Carmichael.
Abstract
Stroke is an age-related disease. Recovery after stroke is associated with axonal sprouting in cortex adjacent to the infarct. The molecular program that induces a mature cortical neuron to sprout a new connection after stroke is not known. We selectively isolated neurons that sprout a new connection in cortex after stroke and compared their whole-genome expression profile to that of adjacent, non-sprouting neurons. This 'sprouting transcriptome' identified a neuronal growth program that consists of growth factor, cell adhesion, axonal guidance and cytoskeletal modifying molecules that differed by age and time point. Gain and loss of function in three distinct functional classes showed new roles for these proteins in epigenetic regulation of axonal sprouting, growth factor-dependent survival of neurons and, in the aged mouse, paradoxical upregulation of myelin and ephrin receptors in sprouting neurons. This neuronal growth program may provide new therapeutic targets and suggest mechanisms for age-related differences in functional recovery.Entities:
Mesh:
Year: 2010 PMID: 21057507 PMCID: PMC3059556 DOI: 10.1038/nn.2674
Source DB: PubMed Journal: Nat Neurosci ISSN: 1097-6256 Impact factor: 24.884
Figure 1Experimental approach and laser capture microdissection of sprouting neurons after stroke. (a) Stroke was produced by permanently occluding two anterior branches of the distal middle cerebral artery over the parietal cortex and transiently occluding bilateral jugular veins. Two different fluorescent conjugates of the tracer cholera toxin B subunit (CTB) were sequentially injected into the same site of forelimb sensorimotor cortex, the first at the time of stroke (Alexa 488–CTB) and the second at 2/3 the volume either 7 or 21 d after stroke (Alexa 647–CTB). Neurons that project to this forelimb sensorimotor site at the time of stroke are labeled with Alexa 488–CTB; neurons that establish a projection to this site only after stroke are labeled solely with Alexa 647–CTB. (b) Injection sites from three separate cases. Only mice in which the second tracer injection was entirely within the first were used for further analysis. (c) Young adult sprouting neurons are shown in the top row and sprouting neurons from an aged brain are shown in the bottom row. The left column shows neurons labeled by the first tracer injection; the middle column neurons labeled by the second tracer injection; the right column neurons seen after laser capture of a tracer 2-only neuron. Neurons with double label (non-sprouting neurons; arrowheads) or labeled by CTB-Alexa 647( tracer-2 only, sprouting neurons; arrows) were separately laser-captured in the peri-infarct cortex. Scale bars, 50 μm (c) and 10 μm (b).
Genes Differentially Regulated in Sprouting Neurons at Day 7 in Young Adult
| Neuropilin 1 |
| Neuropilin and toll-like 2 (Neto2) |
| DEK oncogene |
| tyrosine ligase-like family, member 7 |
| Reticulon 4 receptor-like 1/NgR3 (down) |
| COUP-TFI/NR2F1 (down) |
| L1CAM (down) |
| Stromal interaction molecule 2 |
| Neurocalcin delta |
| Calmodulin 3 |
| Calreticulin |
| Calpactin |
| Protein tyrosine phosphatase, non-receptor type 11 |
| Protein tyrosine phosphatase, receptor type, D (Ptprd) |
| Protein tyrosine phosphatase, receptor type, E (Ptpre) |
| Protein phosphatase 1A, magnesium dependent, alpha isoform (Ppm1a), |
| PLCXD3 |
| Dual specificity protein phosphatase 3 |
| Serine/threonine protein phosphatase PP1-beta |
| MAP-kinase activating death domain |
| Phosphatase and tensin homolog |
| JNK2 |
| MAPK9 |
| Protein tyrosine phosphatase, non-receptor type 1 (Ptpn1) (down) |
| Inositol 1,4,5-triphosphate receptor 1 (Itpr1) (down) |
| Dual specificity phosphatase 5 (Dusp5) (down) |
| Protein tyrosine phosphatase 2E (Ptpn21) (down) |
| CD164 |
| integrin alpha-6 |
| UDP-glucose ceramide glucosyltransferase |
| Tetraspanin 5 |
| SNX6 sorting nexin 6 |
| CD47 |
| Cadherin 2 (N-cadherin) |
| Protocadherin 7,9,19 (19 down) |
| Osteopontin |
| Laminin-5beta3 |
| Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 |
| Heparan sulfate (glucosamine) 3-O-sulfotransferase 2 |
| Matrilin 2 |
| Lip1 |
| BCATc |
| Platelet derived growth factor, alpha |
| Fgf13 (down) |
| Bex1 (down) |
| LIM motif-containing protein kinase 2 (Limk2) (down) |
| Insulin-like growth factor binding protein 5 (down) |
| Rab2 |
| RanBP1 |
| RAB6a |
| Ras homolog gene family, member E (Arhe) |
| Rab12 |
| Rab26 |
| Rab22a |
| Afadin |
| Rhoa |
| Rab11a |
| Rab7a |
| Gpr83 (down) |
| Septin 5 (down) |
| Rab9b (down) |
| Ras homolog enriched in brain like 1 Rhebl1 (down) |
| RGS4 (down) |
| Latrophilin 3 (down) |
| GTPase activating protein testicular GAP1 (down) |
| T-cell lymphoma invasion and metastasis 2 (Tiam2) (down) |
| Connector enhancer of kinase suppressor of Ras 2 (down) |
| G protein-coupled receptor 22 (down) |
| Rho family GTPase 1 (Rnd1) (down) |
| RAS, dexamethasone-induced 1 (Rasd1) (down) |
| Gpr149 G protein-coupled receptor 149 (down) |
| Guanylate cyclase 1, soluble, alpha 3 (down) |
| C1nh/Serping 1 |
| Complement C3 |
| CD46 |
| RT1 class Ib, locus Cl (RT1-Cl) (MHCI) |
| RT1 class Ib, locus S3 (RT1-S3) (MHCI) |
| RT1 class I, CE4 (RT1-CE4) (MHCI) |
| Adipsin/complement factor D |
| Complement receptor related protein (Crry) (down) |
| Usp32 |
| Praja ring finger 2 PJA2 |
| HECT type E3 ubiquitin ligase (down) |
| SNF2 histone linker PHD RING helicase (down) |
| Ubiquitin-conjugating enzyme E2 Harrier protein (down) |
| APC |
| Adducing 3 gamma |
| Kif1a |
| Actin, gamma 2 |
| SFRS protein kinase 2 |
| Stathmin 3/SCLIP |
| Stathmin 4/RB3 |
| Protein kinase A anchoring protein 11 |
| calsyntenin 1 |
| A kinase anchor protein 13 |
| Tumor protein, translationally-controlled 1 |
| Kelch domain containing 3 (Klhdc3) |
| Olfactomedin 3/Optimedin |
| Peroxiredoxin 1 |
| Destrin |
| Doublecortin-like kinase 1 |
| Doublecortin and calcium/calmodulin-dependent protein kinase-like 1 |
| Cyclin-dependent kinase inhibitor 1B |
| Kinesin family member 5B |
| Microtubulue associated protein 4 |
| Actin related protein 2/3 complex, subunit 4 |
| Desmoglein 1 gamma |
| Actin-related protein 3 (down) |
| Retinitis pigmentosa 2 (down) |
| Kinesin-like 7 |
| Kelch-like 23 (down) |
| Bcl11b/Ctip2 |
| Gro/TLE |
| Kruppel-like factor 7 |
| Nuclear receptor subfamily 4, group A, member 2 |
| Janus kinase 1 |
| Mesoderm development candidate 2 |
| Mesoderm induction early response 1 |
| TSC-22 |
| Recombining binding protein suppressor of hairless |
| Nuclear factor I/X (Nfix) |
| Id3 |
| Smad1 |
| Luc7l |
| Stat3 |
| Activating transcription factor 2 |
| Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
| MED10--mediator complex subunit 10 |
| LIM domain only 2 |
| Palmdelphin (down) |
| Smad 5 (down) |
| Egr 2 (down) |
| Purkinje cell protein 4 |
| Snap 25a |
| mGluR3 |
| Ganglioside-induced differentiation-associated-protein 1 amyloid precursor protein |
| Synaptotagmin 12 |
| Neuronal regeneration related protein |
| Glutamate receptor, ionotropic, |
| AMPA1 (alpha 1) |
| Complexin 1, Complexin 2 |
| Receptor expression enhancing protein |
| Pantothenate kinase 1 |
| integral membrane protein 2B (Itm2b) vesicle-associated membrane protein, associated protein B and C |
| Neurexin II (down) |
| Neurobeachin (down) |
| adenylate cyclase activating polypeptide 1/PACAP (down) |
| cholinergic receptor, muscarinic 3 (down) |
| neuropeptide Y receptor Y5 (down) |
| synaptotagmin XVII (down) |
| CXCL10 |
| CXCL13 |
| TNFAIP2 tumor necrosis factor, alpha-induced protein 2 |
| TIGIRR-1 |
| CD40/Tnfrsf5, transforming growth factor, beta 3 TGFb3 (down) |
| TNF receptor superfamily, member 11b (osteoprotegerin) (down) |
| Hdac4 |
| Dre1 |
| Nucleolin |
| Replication factor C |
| Kin KIN17 |
| Cyclin G1 |
| REST corepressor 1 |
| NAP1L1 |
| Never in mitosis gene a-related kinase 1 |
| Nucleoporin 88 (down) |
| EP300 (down) |
All genes upregulated in sprouting neurons vs. non-sprouting neurons unless noted as (down).
Genes differentially regulated in sprouting neurons at day 7 in aged adult vs. young adult
| Mip1a/CCL3 |
| Mip1b/CCL4 |
| Mip2/CXCL2 |
| Interleukin 1 receptor antagonist |
| IL-27 |
| Growth differentiation factor 10 |
| ONECUT2 |
| Bone morphogenic protein 1 |
| Filamin A interacting protein |
| Supervillin |
| Actin related protein 2/3 complex, subunit 5-like |
| Actin-related protein 2 |
| Tyrosine ligase-like family member 7, transcript variant 2 |
| Cofilin 1 |
| Plastin 3 (down) |
| Calsyntenin (down) |
| Neurofilament heavy chain (down) |
| Alpha catenin (down) |
| Piccolo |
| Synaptotagmin 1 |
| Synaptic vesicle glycoprotein 2b |
| Synaptophysin (down) |
| Protocadherin X |
| Osteopontin |
| BEN/Alcam/CD166/Sc1 |
| Glypican 3 |
| CEA-related cell adhesion molecule 10 |
| Neurexin 1 |
| Cadherin 8 |
| Spermidine/spermine N1-acetyl transferase |
| Arginase II (down) |
| IGF-1 |
| Epidermal growth factor receptor (Egfr) |
| Glial cell line derived neurotrophic factor family receptor |
| alpha 3 |
| SORCS3 |
| EphA4 |
| Lingo-1 |
| PKCdeleta |
| Phospholipase C, gamma 2 (Plcg2) |
| Regucalcin (down) |
| Homer (down) |
| ARC (down) |
| ATRX |
| HDAC11 |
| Prrx1 |
| Lim Homeobox 9 |
| B cell translocation gene 1 |
| Janus kinase 1, Janus kinase 2 |
| Ring finger protein 29 (Rnf29) |
| Zinc finger protein 560 |
| E2F transcription factor 1 (E2f1) |
| General transcription factor IIa 2 (Gtf2a2) |
| Recombining binding protein suppressor of hairless |
| Egr1 (down) |
| Neuron-derived orphan receptor 1 (down) |
| Atf5 (down) |
| Sec5l1 |
| Chimaerin 1 |
| Rho GDP dissociation inhibitor (GDI) alpha |
| Rho, GDP dissociation inhibitor (GDI) beta |
| Guanylate cyclase 1, soluble, alpha 3 |
| Mas1 oncogene (down) |
| Rab2b (down) |
| Toll-like receptor 2 |
| CD86 |
| Interferon gamma receptor 2 |
| MHC1RT1 class Ib_ locus S3 (RT1-S3) (down) |
Figure 2Cellular pattern of ATRX, IGF1 and Lingo1 expression in the brain after stroke. (a) Nissl-stained photomicrograph of mouse barrel field stroke model. Boxes indicate region of contralateral cortex (left column) and peri-infarct cortex in young adult (middle column) and aged adult (right column). (b–j) Panels for ATRX (b–d), IGF1 (e–g) and Lingo1 (h–j) show immunoreactivity in each condition. Insets: Colocalized staining of ATRX (red) and NeuN (green) is seen as yellow (d). IGF1 staining (red) localizes to astrocytes and not neurons (green) in young adult peri-infarct cortex (f). In aged adult peri-infarct cortex, IGF1 (red) co-localizes to NeuN positive neurons (green) (g). Lingo1 staining (red) localizes to NeuN positive neurons (green) in aged peri-infarct cortex (j). Scale bars, 1 mm (a), 50 μm (b–d) and 20 μm (insets).
Figure 3Quantitative connectional mapping. (a) Timeline of experimental design for all in vivo axonal tracer experiments. Mice received a sham surgery or stroke, followed 1 week later by siRNA or drug delivery. Three weeks later biotinylated dextran amine (BDA) was microinjected into forelimb motor cortex. (b,c) The cortex was then removed, flattened, tangentially cut (b) and stained for cytochrome oxidase (c) and BDA in the same sections. (d,e)The location of BDA-labeled axons was digitally mapped in x, y coordinates relative to the injection site. (d) The quantitative connectional map of forelimb sensorimotor connections in sham-operated animals (n = 5). (e) The quantitative connectional map of forelimb sensorimotor cortex connections after stroke (n = 7). (f) Cytochrome oxidase staining in layer IV identifies the mouse somatosensory body map2 after stroke. (g) Each connectional map was registered to the somatosensory body map from the same brain to produce a group connectional and functional map of cortex. Axonal sprouting was identified when a pattern of cortical connections was precisely mapped and statistically different across treatment conditions. Scale bars, 1 mm.
Figure 4ATRX function in post-stroke axonal sprouting. (a) Knockdown of ATRX by siRNA reduced axonal outgrowth in vitro compared to scrambled siRNA treatment. ATRX overexpression induced axonal sprouting compared to expression of GFP alone. (b) Axon numbers in normal control or peri-infarct cortex layer 2/3 with Atrx siRNA or scrambled siRNA. (c) Sham, non stroke forelimb motor cortex connections (blue, n = 10) compared to those from Atrx siRNA siRNA group (red, n = 12). The blue label indicates the position of axons projecting from motor cortex summed from the entire sample of mice in the sham, non-stroke condition. The red label indicates that position of axons from the entire sample of mice treated with Atrx siRNA. The dark blue is the areas of dense overlap of the two projection systems. There was no significant difference in the pattern of cortical connections between normal (non-stroke, sham operated (d) Quantitative connectional map of forelimb sensorimotor connections in stroke + scrambled siRNA (blue, n = 11) and stroke + ATRX siRNA (red, n = 12), registered to the body map of underlying cortex with stroke. Dark blue shows area of dense overlap of connections in the two conditions. There is a significant increase in motor cortex projections between stroke + scrambled siRNA and stroke + ATRX siRNA. (e) Polar plots of axonal label from studies in (d). Shaded regions represent 70th percentile of the distances of labeled axons from the injection site; weighted polar vectors represent the normalized distribution of the number of points in a given segment of the graph. There was a significant difference in distribution of cortical projections between stroke + Atrx siRNA (red) and stroke + scrambled siRNA (blue) and between stroke + scrambled siRNA (blue) and non-stroke vehicle (yellow), and no significant change between stroke + Atrx siRNA (red) and non-stroke vehicle (yellow) (n = 10, P > 0.05). Scale bars, 1 mm. Error bars, s.d.; @, * and ** indicate a significant difference compared to saline normal control, GFP control and scrambled siRNA stroke, respectively.
Figure 5IGF1 maintains neuronal viability after stroke. (a) There was no significant difference in the pattern of cortical connections between stroke + saline (n = 5) and stroke + IGF1 (n = 7). (b) There was no significant change in the polar distribution of connections with IGF1 administration compared to stroke + saline (P > 0.05). (c) There was a significant loss of cortical connections between stroke + saline (n = 5) and stroke + JB1 (n = 8). (d) There was a significant decrease in polar distribution of connections with IGF1 blockade (P < 0.001). (e) Photomicrographs of neurons in peri-infarct cortex, showing no change in number across IGF1 treatment conditions. (f) (f) Effects of IGF1 and JB1 on neuronal number in layer 5 in normal control or peri-infarct cortex. IGF1 or JB1 were delivered beginning 7 days after stroke. Stroke (n = 6) induces neuronal cell death in peri-infarct cortex (p < 0.01). This neuronal death is not altered by delivery of IGF1 (n = 5, p > 0.05) or vehicle (n = 5, p > 0.05) into peri-infarct cortex. However, IGF1 blockade with JB1 + hydrogel significantly (n = 5, p < 0.05) increases cell death in peri-infarct cortex when compared to the saline + hydrogel (n = 5) –treated animals post-stroke. (g) Photomicrographs of neurons in peri-infarct cortex, showing decrease in number of neurons with JB1-induced IGF1 signaling blockade. Scale bars, 500 μm (c,g) and 1 mm (a,b,d,e). Note that the location of BDA tracer injection was more lateral in ATRX studies (Fig. 4) than in IGF1/JB1 and Lingo1-Fc/NgR1/NgR2 studies, the latter two of which use the same tracer coordinates; this produces slightly different patterns of intracortical connections. Error bars, s.d, *** p < 0.001 and ** p < 0.01 indicate a significant difference compared to normal control; # < 0.05 indicates a significant difference compared to stroke saline + hydrogel.
Figure 6Lingo1/NgR1 restricts cortical axonal sprouting after stroke. Quantitative connectional maps of forelimb motor connections with NgR1 signaling blockade after hydrogel delivery of Lingo1-Fc + stroke (n = 6) versus hydrogel control-Fc + stroke (n = 7). (a) Lingo1-Fc release into peri-infarct cortex induced a significantly different pattern of forelimb motor cortex connections. (b) Registration of motor cortical connections with the underlying cytochrome oxidase body map shows that Lingo1-Fc blocked the connections that form lateral and rostral to mouse somatosensory cortex, in secondary somatosensory cortex and motor cortex. (c) Polar analysis of forelimb sensorimotor connections from same maps. Lingo1-Fc induced a significant increase in motor cortex connections in the sites seen in the body map registration motor cortex, SI and SII (P < 0.001). (d). Quantitative connectional map of forelimb sensorimotor connections in NgR1 knockout mice with stroke (n = 5) versus control mouse stroke (n = 5). There was a significant increase in the pattern of cortical connections in NgR1 knockout. (e) Registering the underlying mouse body map to the motor cortical projections indicates that new projections could be seen in the NgR1 knockout in lateral SI, SII and to a lesser extent in motor cortex. (f) Polar analysis of forelimb motor connections in stroke + NgR1 knockout versus control. Significantly different connections were seen in motor and lateral somatosensory regions (P < 0.005). Scale bars, 1 mm.